Placing and WRAP Retail Offer

Summary by AI BETAClose X

MedPal AI Plc has conditionally raised approximately £527,000 through a placing of 21,080,000 new ordinary shares at 2.5 pence per share, a 13% discount to the previous day's closing price. The company is also conducting a separate WRAP retail offer. Proceeds from both will fund working capital for pharmacy operations, enabling increased stock levels and a wider range, and support a digital marketing campaign for MedPal.clinic. Following admission of the placing shares, expected around March 26, 2026, the total number of ordinary shares with voting rights will be 476,234,640.

Disclaimer*

Medpal AI PLC
20 March 2026
 

 

 

20 March 2026

 

MedPal AI Plc

("MedPal AI" or the "Company")

 

Placing and WRAP Retail Offer

 

MedPal AI (AIM: MPAL, FRA: Z1N) the UK digital health and AI company, is pleased to announce that it has conditionally raised approximately £527,000 ("Placing") by way of the issue of 21,080,000 new ordinary shares ("Placing Shares") at a price of 2.5 pence per share ("Placing Price").  The Placing Price represents a 13% discount to the closing mid-price of the Company's ordinary shares on 19 March 2026.

The Company is also offering new ordinary shares to investors via a WRAP retail offer, which will be announced separately.

The proceeds from the Placing and the WRAP retail offer (together the "Fundraise") will be used to provide working capital for the Company's pharmacy operations to enable it to carry both higher levels and a wider range of stock to meet rising customer demand and also to fund a digital marketing campaign for MedPal.clinic.

The Placing is conditional on the Placing Shares, which will be issued credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares, being admitted to trading on AIM ("Admission").  Admission of the Placing Shares is expected to occur on or around 26 March 2026.

For the avoidance of doubt, the WRAP retail offer is not part of the Placing. Completion of the WRAP retail offer is conditional, inter alia, upon the completion of the Placing but completion of the Placing is not conditional on the completion of the WRAP retail offer.

 

Total voting rights

Immediately following Admission and excluding any shares to be issued subject to the WRAP, the Company will have 476,234,640 Ordinary Shares in issue. Accordingly, the total number of Ordinary Shares in the Company with voting rights will be 476,234,640. This figure may be used by shareholders in the Company as denominator for the calculations by which they may determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company are responsible for the contents of this announcement.

 

MedPal AI plc

Jason Drummond

 

www.medpalplc.com

Cairn Financial Advisers LLP

Louise O'Driscoll/Jo Turner

 

+44(0) 20 7213 0880

Clear Capital Markets Limited

Bob Roberts

+44(0) 20 3869 6080

 

 

Winterflood Retail Access Platform

Sophia Bechev, Kaitlan Billings

WRAP@winterflood.com

+44(0) 20 3100 0214

 

 

Further information on the Company can be found on its website at www.medpalplc.com

 

The Company's LEI is 984500EDP8B0A14CBA61.

 

This announcement should be read in its entirety. In particular, the information in the "Important Notices" section of the announcement should be read and understood.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings